Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.

Fedratinib adverse events gastrointestinal mitigation strategies myelofibrosis myelofibrosis symptom assessment form (MSAF) spleen response

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
05 Jun 2024
Historique:
medline: 5 6 2024
pubmed: 5 6 2024
entrez: 5 6 2024
Statut: aheadofprint

Résumé

The phase 3b FREEDOM trial (ClinicalTrials.gov: NCT03755518) evaluates efficacy/safety of fedratinib in intermediate- or high-risk myelofibrosis patients with platelet count ≥50 × 10

Identifiants

DOI: 10.1080/10428194.2024.2346733 PMID: 38838026
pubmed: 38838026
doi: 10.1080/10428194.2024.2346733
doi:

Banques de données

ClinicalTrials.gov
['NCT03755518']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-11

Auteurs

Vikas Gupta (V)

Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
ORCID: 0000-0002-1419-8607

Abdulraheem Yacoub (A)

Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Hospital, Kansas City, KS, USA.

Ruben A Mesa (RA)

Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Claire N Harrison (CN)

Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Alessandro M Vannucchi (AM)

Department of Experimental and Clinical Medicine, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Università di Firenze, Florence, Italy.

Jean-Jacques Kiladjian (JJ)

Department of Hematology, Hôpital Saint-Louis, Université Paris Cité, Paris, France.

Hans-Joachim Deeg (HJ)

Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Salman Fazal (S)

Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, USA.

Lynda Foltz (L)

Division of Hematology, University of British Columbia, Vancouver, Canada.

Ryan J Mattison (RJ)

Department of Internal Medicine and Medical Oncology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA.

Carole B Miller (CB)

Department of Medical Oncology, Ascension Saint Agnes Cancer Institute, Baltimore, MD, USA.

Vinod Parameswaran (V)

Department of Hematology, Transplantation, and Oncology, Avera Cancer Institute, Sioux Falls, SD, USA.

Patrick Brown (P)

Bristol Myers Squibb, Princeton, NJ, USA.

Christopher Hernandez (C)

Bristol Myers Squibb, Princeton, NJ, USA.

Jia Wang (J)

Bristol Myers Squibb, Princeton, NJ, USA.

Moshe Talpaz (M)

Department of Hematology-Oncology, University of Michigan, Ann Arbor, MI, USA.

Classifications MeSH